Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 3/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.98 |
| ▸ | DRD2 | P14416 | 6/20 | 0.81 |
| ▸ | DRD5 | P21918 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7203243 | 0.99 | DRD1 (1.00) | DRD1KDM4EMAPTMTORCYP2D6 | |
| Bromide SCHEMBL11288446 | 0.99 | KDM4E (1.00) | DRD1KDM4EMAPTMTORCYP2D6 | |
| SCHEMBL10745918 | 0.86 | DRD1 (0.75) | DRD1KDM4EMAPTMTORCYP2D6 | |
| Hydrochloric Acid SCHEMBL10747243 | 0.85 | DRD1 (0.76) | DRD1KDM4EMAPTMTORCYP2D6 | |
| SCHEMBL11605631 | 0.85 | DRD2 (0.76) | DRD1KDM4EMAPTMTORCYP2D6 | |
| Hydrochloric Acid SCHEMBL10345839 | 0.84 | DRD1 (0.74) | DRD1KDM4EMAPTMTORCYP2D6 | |
| SCHEMBL14510732 | 0.83 | DRD1 (0.82) | DRD1KDM4EMAPTMTORCYP2D6 | |
| SCHEMBL11157379 | 0.82 | DRD1 (0.70) | DRD1KDM4EMAPTMTORCYP2D6 | |
| Bromide SCHEMBL11539891 | 0.82 | KDM4E (0.72) | DRD1KDM4EMAPTMTORCYP2D6 | |
| SCHEMBL18085055 | 0.82 | DRD1 (0.73) | DRD1KDM4EMAPTMTORCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771678-B2 | Therapeutic agent for neuropathy in organic acidemia of which mechanism relies on increase in cAMP | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2023-10-03 | — | — | US | claimed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| CN-117255689-A | NMN and derivatives for the treatment of depression and/or anxiety in patients suffering from one form of Parkinson's disease | 努瓦米德公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSITY OF DELHI (IN) | 2023-10-05 | — | — | US | disclosed |
| US-11771678-B2 | Therapeutic agent for neuropathy in organic acidemia of which mechanism relies on increase in cAMP | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2023-10-03 | — | — | US | disclosed |
| EP-4178564-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | The McLean Hospital Corporation (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2015095257-A2 | MANAGING VISUAL DYSFUNCTION OR LOSS OF VISION FOR DIABETIC SUBJECTS | EMORY UNIVERSITY (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-0002327-B1 | PHARMACOLOGICALLY ACTIVE 6-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, METHOD OF PREPARING THEM AND INTERMEDIATES | SMITHKLINE BECKMAN CORPORATION (US) | 1982-08-04 | — | — | EP | disclosed |
| US-4342686-A | Intermediates for preparing 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1982-08-03 | — | — | US | disclosed |
| US-4265889-A | DOPAMINERGIC, HYPOTENSIVE | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4265889-A | DOPAMINERGIC, HYPOTENSIVE | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4192872-A | ANTI -PARKINSONISM ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4165372-A | 6-Carboxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds and use as dopaminergic agents | SMITHKLINE CORPORATION (US) | 1979-08-21 | — | — | US | disclosed |
| EP-0002327-A1 | Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-13 | — | — | EP | disclosed |
| EP-0002327-A1 | Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4052506-A | BENZAZEPINES | SMITHKLINE CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NCOR1, NLN, NCOR2 | DRD1 2301/4885KDM4E 2166/4885MAPT 42/4885 |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | DRD1 1866/4885KDM4E 4190/4885MAPT 38/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | DRD1 4783/4885KDM4E 1110/4885MAPT 4150/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | DRD1 4783/4885KDM4E 1110/4885MAPT 4150/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | DRD1 717/4885KDM4E 4813/4885MAPT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.